Cover Image
市場調查報告書

Beijing Minhai Biotechnology Co., Ltd :產品平台分析

Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 315709
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
Beijing Minhai Biotechnology Co., Ltd :產品平台分析 Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016
出版日期: 2016年12月21日 內容資訊: 英文 50 Pages
簡介

Beijing Minhai Biotechnology Co., Ltd是研究開發、產品化傳染病的預防和治療用疫苗,以有助於人們健康為目標的生物科技企業。

本報告提供Beijing Minhai Biotechnology Co., Ltd的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Beijing Minhai Biotechnology Co., Ltd的基本資料

  • Beijing Minhai Biotechnology Co., Ltd概要
  • 主要資訊
  • 企業資料

Beijing Minhai Biotechnology Co., Ltd :R&D概要

  • 主要的治療範圍

Beijing Minhai Biotechnology Co., Ltd :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Beijing Minhai Biotechnology Co., Ltd :開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Beijing Minhai Biotechnology Co., Ltd :藥物簡介

  • pneumococcal polysaccharide vaccine (23-valent)
  • hepatitis A vaccine
  • hepatitis B vaccine
  • meningococcal conjugate vaccine serogroups A, C, Y and W135
  • cholera vaccine (trivalent)
  • diphtheria + tetanus + pertussis (acellular) vaccine
  • haemophilus influenzae conjugate vaccine type B
  • hepatitis A + hepatitis B vaccine
  • influenza vaccine (split virion)
  • meningococcal conjugate vaccine (tetravalent)
  • meningococcal polysaccharide vaccine (tetravalent)
  • pneumococcal conjugate vaccine 13-valent
  • rabies vaccine MRC-5
  • enterovirus 71 vaccine
  • herpes vaccine
  • human papillomavirus vaccine (tetravalent)
  • influenza vaccine H1N1
  • meningococcal vaccine serogroup B
  • pneumococcal conjugate vaccine (15-valent)
  • rotavirus vaccine (pentavalent)

Beijing Minhai Biotechnology Co., Ltd :開發平台分析

  • 各給藥途徑
  • 各分子類型

Beijing Minhai Biotechnology Co., Ltd :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08169CDB

Summary

Global Markets Direct's, 'Beijing Minhai Biotechnology Co Ltd - Product Pipeline Review - 2016', provides an overview of the Beijing Minhai Biotechnology Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Beijing Minhai Biotechnology Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Beijing Minhai Biotechnology Co Ltd
  • The report provides overview of Beijing Minhai Biotechnology Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Beijing Minhai Biotechnology Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Beijing Minhai Biotechnology Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Beijing Minhai Biotechnology Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Beijing Minhai Biotechnology Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beijing Minhai Biotechnology Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Beijing Minhai Biotechnology Co Ltd Snapshot 7
  • Beijing Minhai Biotechnology Co Ltd Overview 7
  • Key Facts 7
  • Beijing Minhai Biotechnology Co Ltd - Research and Development Overview 8
  • Key Therapeutic Areas 8
  • Beijing Minhai Biotechnology Co Ltd - Pipeline Review 11
  • Pipeline Products by Stage of Development 11
  • Pipeline Products - Monotherapy 12
  • Pipeline Products - Combination Treatment Modalities 13
  • Pipeline Products - Partnered Products 14
  • Partnered Products/Combination Treatment Modalities 15
  • Beijing Minhai Biotechnology Co Ltd - Pipeline Products Glance 16
  • Beijing Minhai Biotechnology Co Ltd - Late Stage Pipeline Products 16
  • Pre-Registration Products/Combination Treatment Modalities 16
  • Phase III Products/Combination Treatment Modalities 17
  • Beijing Minhai Biotechnology Co Ltd - Clinical Stage Pipeline Products 18
  • Phase I Products/Combination Treatment Modalities 18
  • Beijing Minhai Biotechnology Co Ltd - Early Stage Pipeline Products 19
  • IND/CTA Filed Products/Combination Treatment Modalities 19
  • Preclinical Products/Combination Treatment Modalities 20
  • Beijing Minhai Biotechnology Co Ltd - Drug Profiles 21
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 21
  • Product Description 21
  • Mechanism Of Action 21
  • R&D Progress 21
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • (hepatitis A + hepatitis B) vaccine - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • (measles + rubella + varicella) vaccine - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • cholera (trivalent) vaccine - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Enterovirus [serotype EV-A71] vaccine - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • Haemophilus influenzae B vaccine - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • hepatitis A vaccine - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • hepatitis B vaccine - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • herpes simplex virus vaccine - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • herpes zoster vaccine - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • human papillomavirus (quadrivalent) vaccine - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • influenza (split virion) vaccine - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • influenza [strain A/H1N1] vaccine - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • influenza [strain A/H7N9] vaccine - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • meningococcal [serotype B] vaccine - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • mumps vaccine - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • pneumococcal (13-valent) vaccine - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • pneumococcal (23-valent) vaccine - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • rabies vaccine - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • rotavirus (pentavalent) vaccine - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • varicella zoster vaccine - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • Beijing Minhai Biotechnology Co Ltd - Pipeline Analysis 45
  • Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Route of Administration 45
  • Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Molecule Type 46
  • Beijing Minhai Biotechnology Co Ltd - Dormant Projects 47
  • Beijing Minhai Biotechnology Co Ltd - Locations And Subsidiaries 48
  • Head Office 48
  • Appendix 49
  • Methodology 49
  • Coverage 49
  • Secondary Research 49
  • Primary Research 49
  • Expert Panel Validation 49
  • Contact Us 49
  • Disclaimer 50

List of Tables

  • Beijing Minhai Biotechnology Co Ltd, Key Facts 7
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Indication, 2016 9
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Stage of Development, 2016 11
  • Beijing Minhai Biotechnology Co Ltd - Monotherapy Products in Pipeline, 2016 12
  • Beijing Minhai Biotechnology Co Ltd - Combination Treatment Modalities in Pipeline, 2016 13
  • Beijing Minhai Biotechnology Co Ltd - Partnered Products in Pipeline, 2016 14
  • Beijing Minhai Biotechnology Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 15
  • Beijing Minhai Biotechnology Co Ltd - Pre-Registration, 2016 16
  • Beijing Minhai Biotechnology Co Ltd - Phase III, 2016 17
  • Beijing Minhai Biotechnology Co Ltd - Phase I, 2016 18
  • Beijing Minhai Biotechnology Co Ltd - IND/CTA Filed, 2016 19
  • Beijing Minhai Biotechnology Co Ltd - Preclinical, 2016 20
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Route of Administration, 2016 45
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Molecule Type, 2016 46
  • Beijing Minhai Biotechnology Co Ltd - Dormant Developmental Projects,2016 47

List of Figures

  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Top 10 Indication, 2016 9
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Stage of Development, 2016 11
  • Beijing Minhai Biotechnology Co Ltd - Monotherapy Products in Pipeline, 2016 12
  • Beijing Minhai Biotechnology Co Ltd - Combination Treatment Modalities in Pipeline, 2016 13
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Route of Administration, 2016 45
  • Beijing Minhai Biotechnology Co Ltd - Pipeline by Molecule Type, 2016 46
Back to Top